[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"miscarriage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:miscarriage":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,43,74,103,134,161,183,205,235,255,278,310],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100513753","is-decreased-ovarian-reserve-related-to-an-increased-number-of-previous-early-miscarriages-100513753",false,"NCT05969574","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?","Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages? A Prospective Observational Study","Inclusion Criteria:\n\n1\\. All participants with at least 1 previous pregnancy, who are assessed in one of our clinics (ART Fertility Clinics Abu Dhabi, Al Ain, Dubai)\n\nExclusion Criteria:\n\n1. Severe male factor (azoospermia, cryptozoospermia, severe oligoasthenoteratozoospermia (OAT))\n2. Severe Endometriosis and adenomyosis based on positive anamnesis or ultrasound performed in our center during the first consultation\n3. Uterine abnormalities (e.g. fibroids, different degrees of uterine septum), diagnosed by ultrasound\n4. History of ovarian surgery, chemotherapy, or radiation therapy\n5. Known genetic disorder or chromosomal abnormality\n6. BMI \\>40Kg\u002Fm2\n7. Currently using hormonal contraception or hormone replacement therapy","FEMALE",{"count":18,"type":19},2059,"ESTIMATED","OBSERVATIONAL","This study aims to explore the potential correlation between decreased ovarian reserve and previous history of early miscarriage.",[23,24,25,26],"Infertility, Female","Miscarriage","Miscarriage, Recurrent","IVF",[28,29,26],"miscarriage","infertility","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2023-09-09",{"date":38,"type":19},"2026-12-31",{"name":40,"class":41},"ART Fertility Clinics LLC","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100499952","hysteroscopy-vs-endouterine-aspiration-in-the-management-of-trophoblastic-retention-100499952","NCT05789940","Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention","Hysteroscopy Versus Endouterine Aspiration in the Management of Trophoblastic Retention: A Prospective Randomized Multicenter Study","HARET","Inclusion Criteria:\n\n* Management for trophoblastic retention after early spontaneous miscarriage (\\\u003C14 weeks of amenorrhea)\n* Diagnosis of intrauterine trophoblastic retention by endovaginal pelvic ultrasound\n* Shared decision for surgical management\n\nExclusion Criteria:\n\n* Known uterine malformation\n* Patient who has received surgical treatment for current intrauterine retention\n* Patient with an intrauterine device (IUD)\n* Pregnancy obtained by medically assisted procreation\n* Indication for emergency surgical management for haemostatic purposes\n* Failure to obtain free, informed and written consent after a period of reflection\n* Person not affiliated or beneficiary of a national health insurance system\n* Person protected by law, under guardianship or curatorship\n* Person participating in other interventional research involving the human person","18 Years","42 Years",{"count":54,"type":19},220,"INTERVENTIONAL",[57],"NA","Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.\n\nAim: The main objective is to compare the efficacy of management by endo-uterine aspiration vs. management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.\n\nMethods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.\n\nPatients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:\n\n* Arm A: 110 patients treated by operative hysteroscopy\n* Arm B: 110 patients treated by endo-uterine aspiration",[24],[24,61,62,63,64],"Hysteroscopy","Aspiration","Fertility","Synechiae","2026-06-17",{"date":31,"type":34},{"date":68,"type":34},"2023-09-18",{"date":70,"type":19},"2029-09-18",{"name":72,"class":41},"University Hospital, Montpellier",4,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":51,"enrollmentInfo":82,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100560398","periodontal-disease-microbiota-and-miscarriage-100560398","NCT06576622","PERIodontal Disease, Microbiota and Miscarriage","Status Report on Periodontal Status and Oral Microbiota Women Who Have Suffered Repeated Miscarriages: a Pilot Study","PERI2M","Inclusion Criteria:\n\n* women whom had repeated miscarriages\n* at least 6 natural teeth\n\nExclusion Criteria:\n\n* under antibiotic prebiotic or probiotics treatment one month prior to the study\n* with high infection risk (HIV,...)",{"count":83,"type":19},30,"Cross-sectional non-interventional observational pilot study recruiting women whom had repeated miscarriages (= at least 3 miscarriages).The information will be collected during a routine maintenance, complete oral clinical and radiological examination (assessment carious, periodontal, mucosal and functional), which is part of the routine assessment in the service of odontology from Toulouse University Hospital.\n\nSaliva and subgingival plaque samples, classically carried out in routine dental surgery as part of the health check-up oral, will be used to carry out bacterial assays.",[24,86],"Parodontitis",[88,89,90,91,92],"REPEATED MISCARRIAGES","Porphyromonas gingivalis","SALIVA","BIOLOGICAL SAMPLES","subgingival plaque","2026-05-07",{"date":95,"type":34},"2026-05-12",{"date":97,"type":34},"2024-11-29",{"date":99,"type":19},"2026-12-30",{"name":101,"class":41},"University Hospital, Toulouse",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":111,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":55,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":102},"100593861","walk-with-me-wwm-for-perinatal-grief-100593861","NCT07011940","Walk With Me (WWM) for Perinatal Grief","PeriGrief-II","Inclusion Criteria:\n\n* Within the first month of pregnancy or early infant loss\n* Reside in the United State\n* Speak and read either English or Spanish at a 6th grade reading level\n* 15 or older\n\nExclusion Criteria:\n\n* Not pregnant or has not experienced an early infant loss\n* Does not reside in the United State\n* Does not speak and read either English or Spanish at a 6th grade reading level\n* 14 or younger",true,"ALL","15 Years",{"count":114,"type":19},300,[57],"The goal of this clinical trial is to learn if the Along With Me web-based intervention works to decrease posttraumatic stress symptoms and suicidal ideation among bereaved parents following pregnancy and early infant loss. It will also learn whether peer guides provide additional improvements on these outcomes.\n\nThe main questions it aims to answer are:\n\n• Do people who receive Along With Me or Along With Me plus a Peer Guide compared to services as usual have lower posttraumatic stress symptoms and suicidal ideation than those who do not receive the intervention?\n\nResearchers will compare Along With Me and Along With Me plus a Peer Guide to services as usual (referrals made in the hospital setting) to see if Along With Me works to prevent and address posttraumatic stress symptoms and suicidal ideation.\n\nParticipants will:\n\n* Receive access to a mobile app with approximately 10 therapeutic modules about how to manage grief and other symptoms.\n* Receive check-ins with a Peer Guide (in the Peer Guide condition only)",[118,119,120,24,121,122],"Grief","Post Traumatic Stress Disorder","Suicidal Ideation","Stillbirth","Infant Death","NOT_YET_RECRUITING","2026-03-04",{"date":126,"type":34},"2026-03-06",{"date":128,"type":19},"2026-07-01",{"date":130,"type":19},"2027-08-31",{"name":132,"class":133},"Oregon Research Behavioral Intervention Strategies, Inc.","INDUSTRY",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":102},"100482067","cohort-of-patients-presenting-unexplained-recurrent-miscarriages-and-identification-of-early-miscarriage-recidivism-factors-100482067","NCT05557201","Cohort of Patients Presenting Unexplained Recurrent Miscarriages and Identification of Early Miscarriage Recidivism Factors","FALCO","Inclusion Criteria:\n\n* Age 18 to 50 years\n* Patients who have had 3 (or more) early pregnancy losses occurring before 14 weeks of amenorrhea and\u002For at least 3 implantation failures.\n* Patients who have been informed and have not objected to participating in the study.\n* Patients covered by a social security system.\n\nExclusion Criteria:\n\n* patients who do not agree the use of their data\n* Patients on AME\n* Patients under legal protection","50 Years",{"count":143,"type":19},700,"About 1 to 3% of women of childbearing age suffer repeated early spontaneous miscarriages (RCF) defined by at least 3 fetal losses before 14 weeks of gestation. RCFs may be linked to parental chromosomal abnormalities, congenital or acquired uterine abnormalities, hormonal causes (e.g. type 1 and 2 diabetes, ovarian failure), infectious etiology, constitutional or acquired thrombophilia or sickle cell disease.\n\nThe presence of antiphospholipid antibodies, antithyroid and anti-transglutaminase antibodies in approximately 10% of cases suggests an autoimmune origin for these fetal losses. The role of other antibodies, in particular non-conventional antiphospholipid antibodies, remains to be established. Indeed half of RCF cases are thought to be due to an immunological dysregulation of the mother leading to a decrease in tolerance to the fetus. Several studies have shown immune abnormalities, such as an imbalance of pro and anti-inflammatory cytokines, an increase in cytotoxic cells and a defect in regulatory cells in the blood of patients. The assessment of these immune abnormalities is not currently performed routinely in France in women presenting with recurrent early miscarriages. When one of these known causes is excluded, it is unexplained RCF which represents 50% of RCF. Over half of these women with RCF may be linked to aneuploidies and primary spontaneous recurrent abortions. Assessing the degree of aneuploidy and the genetic origin of foetal losses remains difficult to date, as examination of the miscarriage product is rarely available, due to the spontaneous nature of the loss.\n\nAn implantation failure (IF) is defined as the absence of pregnancy following the transfer of a good-quality embryo into the uterine cavity. These implantation failures can be due to embryonic factors, maternal factors, or caused by inappropriate stimulation and\u002For difficult transfers. In the literature, recurrent implantation failure (RIF) is defined as the absence of pregnancy after 3 attempts of transferring good-quality embryos, taking maternal age into account Setting up a prospective cohort of patients with RFC is an essential step in exploring the aetiological factors of RCF and in order to enable better treatment.",[24,146],"Early Pregnancy Loss",[24,148,149,150,151],"Prognostic factors","Biological collection","recurrent early pregnancy losses","repeated implantation failure","2025-12-12",{"date":154,"type":34},"2025-12-19",{"date":156,"type":34},"2022-10-24",{"date":158,"type":19},"2029-10",{"name":160,"class":41},"Assistance Publique - Hôpitaux de Paris",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":55,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":102},"100601396","use-of-aromatase-inhibitor-before-misoprostol-in-medical-termination-of-miscarriage-100601396","NCT07109947","Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage","Comparison Between the Use of Aromatase Inhibitor Before Misoprostol and Use of Misoprostol Alone in Medical Termination of Miscarriage","Inclusion Criteria:\n\n* Missed or anembryonic pregnancy.\n* Gestational age from 4 weeks to 26 weeks of pregnancy (confirmed by ultrasound scanning on first day of admittance).\n* Hemoglobin level more than 9g\u002Fl.\n* Closed cervix.\n* No product of conception in the cervical canal.\n\nExclusion Criteria:\n\n* Previous attempt to terminate the pregnancy.\n* Molar pregnancy\n* Abnormal uterine lesions such as fibroids or congenital mal formations.\n* Pregnancy despite of intrauterine contraceptive device.\n* Medical disorders as cardiac, renal or hemorrhagic diseases.\n* BMI more than 35 kg\u002Fm2.\n* Known hypersensitivity to any of the medication used.","45 Years",{"count":170,"type":19},70,[57],"Abortion is one of the most common complications of pregnancy. Missed abortion is a type of abortions, occurs in 15%-20% of clinically diagnosed pregnancies and is defined as the retention of pregnancy products in the uterus for several days or weeks after death of the fetus.",[24],"2025-07-31",{"date":176,"type":34},"2025-08-07",{"date":178,"type":34},"2025-07-10",{"date":180,"type":19},"2025-12-10",{"name":182,"class":41},"Aswan University",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":55,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":102},"100550872","phase-2-letrozole-and-misoprostol-for-early-pregnancy-loss-management-100550872","NCT06452719","Letrozole and Misoprostol for Early Pregnancy Loss Management","Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study","LeMi","Inclusion Criteria:\n\n* Able to participate in the informed consent process and provide a signed and dated consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Access to working mobile phone\n* English-speaking\n* Age 18 years or older\n* Confirmed diagnosis of intrauterine embryonic\u002Ffetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)\n\nExclusion Criteria:\n\n* Incomplete or inevitable abortion\n* Contraindication of allergy to letrozole or misoprostol\n* Unable to return for clinic-based follow-up\n* Twin or multiple pregnancy",{"count":83,"type":19},[193],"PHASE2","A pilot cohort study to preliminarily investigate the efficacy of pretreatment with letrozole 10 mg daily for three consecutive days followed by treatment with misoprostol 800 mcg vaginally for medical management of early pregnancy loss in a US population. Patients will be followed to assess efficacy of this treatment regimen, as well as additional interventions needed, side effects, adverse events, and patient acceptability.",[146,196,24],"Miscarriage in First Trimester",{"date":198,"type":34},"2025-08-05",{"date":200,"type":34},"2024-08-22",{"date":202,"type":19},"2026-07-15",{"name":204,"class":41},"University of Pennsylvania",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":110,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":214,"conditions":215,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":73},"100477111","the-heartland-study-100477111","NCT05492708","The Heartland Study","Children's Health in the Heartland Study","Inclusion Criteria:\n\n* Pregnant persons ages 18 or older at time of consent who are ≤20+6 weeks pregnant. Best clinical estimate of gestational age will be utilized for recruitment purposes. Enrollment in the first trimester (≤ 13 + 6) is preferred, but anyone ≤ 20 +6 is permitted.\n* Living in one of the 13 Heartland Study region states at the time of enrollment (Arkansas, Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, or Wisconsin) Optional inclusion of the putative biological father\n\nExclusion Criteria:\n\n* Participants who are not fluent in and\u002For do not fully understand, read, write, or speak the English language.\n* Other inability to provide informed consent to participate",{"count":213,"type":19},2600,"The Heartland Study is a prospective, observational study that will enroll up to 2,600 pregnant participants across the Heartland States in the U.S..\n\nThe objective of the Heartland Study is to address major knowledge gaps concerning the health effects of herbicides on maternal and infant health. The study is being conducted to evaluate the associations between environmental exposures to herbicides during and after pregnancy and reproductive health outcomes. The study is measuring multiple biomarkers of herbicide exposure among pregnant Midwesterners and their partners to evaluate associations with pregnancy and childbirth outcomes, epigenetic biomarkers of exposure, and child development.",[216,217,218,219,220,24,221],"Pregnancy Related","Pregnancy Complications","Birth Defect","Gestational Age and Weight Conditions","Spontaneous Abortion","Exposure to Herbicides",[223,224,225],"pesticide exposure","birth outcomes","biomonitoring","2025-06-25",{"date":228,"type":34},"2025-06-29",{"date":230,"type":34},"2020-01-11",{"date":232,"type":19},"2029-01",{"name":234,"class":41},"Heartland Health Research Alliance",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":102},"100582344","a-prospective-study-evaluating-the-impact-of-conservative-management-on-retained-products-of-conception-and-emv-100582344","NCT06862089","A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV","Inclusion Criteria:\n\n* Recent history of miscarriage or delivery (within the past 8 weeks)\n* Strong willingness to undergo conservative management\n* Hemodynamically stable\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Heavy vaginal bleeding (requiring immediate surgical intervention)\n* Active pelvic or systemic infection (e.g., fever \\>38°C, elevated CRP\u002FWBC)\n* Severe dysfunction of vital organs (heart, liver, or kidney)\n* Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)\n* Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)\n* Placenta accreta spectrum disorders diagnosed during current pregnancy\n* History of uterine artery embolization",{"count":242,"type":19},120,"The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).\n\nThe main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.",[245,24,246],"Retained Products of Conception","Conservative Management","2025-06-12",{"date":249,"type":34},"2025-06-15",{"date":251,"type":34},"2024-10-23",{"date":99,"type":19},{"name":254,"class":41},"Fu Xing Hospital, Capital Medical University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":111,"minAge":51,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":55,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":102},"100511199","exploration-of-allograft-humoral-rejection-in-chronic-histiocytic-intervillositis-100511199","NCT05936333","Exploration of Allograft Humoral Rejection in Chronic Histiocytic Intervillositis","RH-PL","Family Inclusion Criteria:\n\n* Mother and father ≥ 18 years old\n* For mothers in the CHI group :\n\n  * History of a normal pregnancy (full term, alive child) or IUGR\u002FMFIU or miscarriage(s) or abortion followed by at least 1 obstetrical complication such as IUGR, MFIU, miscarriage\n  * Diagnosis of chronic histiocytic intervillitis made by placental anatomopathological examination with CD68+ marking\n* For the mothers of the antiphospholipid syndrom group\n\n  * History of miscarriage(s)\n  * Having an anti-phospholipid syndrome\n* For mothers in the normal pregnancy group:\n\n  * Third consecutive pregnancy of normal course, at term (≥ 36 weeks of amenorrhea) with eutrophic child\n\nFor the mother and father:\n\no Consent to participate in the study and for the participation in the study of at least one child and\u002For the use of existing samples (placenta \u002F fetal DNA) from at least one previous pregnancy with CHI for the CHI group or at least one previous miscarriage for the APS group\n\nFor the father:\n\no Father of the last pregnancy and of the child(ren) participating in the study\n\nExlusion criteria :\n\n* For mothers in the normal pregnancy group:\n\n  o Suspected or confirmed intra-amniotic infection\n* For all the mothers:\n\n  * History of blood transfusion\n  * History of allogeneic organ transplantation\n* For the mother and the father:\n\n  * Person under legal protection (guardianship, curatorship)",{"count":263,"type":19},200,[57],"Chronic histiocytic intervillositis (CHI) is a rare condition with an incidence of 5 in 10,000 pregnancies. This rare condition is associated with placental inflammatory lesions leading to severe and recurrent obstetrical complications: intrauterine growth retardation (IUGR), fetal death in utero and miscarriage. The pathophysiological mechanisms of CHI are poorly understood, while the empirical treatments prescribed to prevent recurrence are cumbersome and of poor efficacy.\n\nRecent findings suggest that an alloimmune response may play a role. In a recent work, the investigators have demonstrated the role of maternal alloantibodies directed against fetal HLA antigens in two patients followed for recurrent IUGR associated with CHI. Their work suggests that a humoral alloimmune response directed against fetal HLA antigens mimics an allograft rejection process.\n\nThe investigators propose to extend the preliminary results obtained in these patients to provide new insights into the pathophysiological mechanisms of CHI, and eventually to predict the risks of fetal loss.",[267,268,269,24],"Chronic Histiocytic Intervillositis","Intrauterine Growth Retardation","Fetal Death in Utero","2024-11-04",{"date":272,"type":34},"2024-11-06",{"date":274,"type":34},"2023-10-11",{"date":276,"type":19},"2025-10-11",{"name":160,"class":41},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":55,"phases":289,"briefSummary":291,"conditions":292,"keywords":297,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":102},"100495002","phase-4-prednisolone-administration-in-patients-with-unexplained-recurrent-miscarriages-100495002","NCT05725512","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages","Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages, PREMI Trial","PREMI","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, a subject must meet all of the following criteria:\n\n* Unexplained recurrent pregnancy loss: defined as the loss of ≥2 pregnancies, without any known cause for RM (parental chromosomal abnormalities, uterine anomalies, acquired or hereditary thrombophilia, endocrine diseases (such as hypothyroidism or diabetes)).\n* The miscarriages include:\n\n  * all consecutive or non-consecutive pregnancy losses before the 24th week of gestation verified by ultrasonography or uterine curettage and histology\n  * non-visualized pregnancies (including biochemical pregnancy losses and\u002For resolved and treated pregnancies of unknown location), verified by positive urine or serum hCG Ectopic and molar pregnancies are not included\n* Age 18 - 39 years at randomization (likelihood of miscarriages due to chromosomal aberrations is higher when age \\> 39 years. Such miscarriages are unlikely to be pre-vented by prednisolone therapy)\n* Conception confirmed by urinary pregnancy test, with estimated gestational age ≤ 7weeks\n* Willing and able to give informed consent in English or Dutch (IC)\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n* Any of the following diagnosis for the recurrent miscarriages\n\n  * Antiphospholipid syndrome (lupus anticoagulant and\u002F or anticardiolipin anti-bodies and\u002For beta-2 glycoprotein \\[IgG or IgM)\n  * Congenital uterine abnormalities (as assessed by 2D or 3d ultrasound, hys-terosonography, hysterosalpingogram or hysteroscopy)\n  * Abnormal parental karyotype\n* Instable or exacerbation of auto-immune diseases such as diabetes, thyroid disease, inflammatory bowel diseases or SLE\n* Inability to conceive within 1 year of recruitment\n* Current treatment with systemic prednisolone or other immune suppressive medication (for any indication)\n* Previous enrolment in the PREMI trial\n* Enrolment in any other trial that studies the effectiveness of an intervention on RM\n* Contraindications to prednisolone use:\n\n  * Known allergy for prednisolone\n  * Acute bacterial infection or parasite infection\n  * Active COVID infection\n  * Systemic sclerosis\n  * Ulcus ventriculi or ulcus duodeni in medical history\n  * Obesity with BMI \\>40\n* Some drugs are known to interact with Prednisolone, and thus women on the following drugs are not eligible to take part in the PREMI trial:\n\n  * Enzyme inducers, such as carbamazepine, fenobarbital, fenytoïne and ri-fampicine\n  * CYP3A inhibitors, such as Cobicistat or Ritonavir\n  * Cyclosporine\n  * Digoxin\n  * Vaccination (with inactivated virus or bacteria) during prednisolone use is possibly less effective","40 Years",{"count":288,"type":19},490,[290],"PHASE4","Recurrent miscarriages (RM) affects 3% of all fertile couples, but remains unexplained in most cases, limiting therapeutic options. Possibly the maternal immune system plays a role in recurrent miscarriage. Prednisolone suppresses the immune system and might enable development of normal pregnancy.\n\nIn this randomized controlled clinical trial the investigators will study the effect of prednisolone on the live birth rate in patients with RM. Secondary, the tolerability and safety for mother and child and the cost-effectiveness is investigated.\n\nIn the study one group of pregnant women with RM and gestational age \\\u003C7 weeks will receive prednisolone, the other group will receive a placebo. Total use of the medicine during this study is 8 weeks, further care during the study is routinely antenatal care. Subjects will be asked to fill in 4 short questionnaires and will have contact with a research nurse at different time points to gain information on the course of the pregnancy and possible side effects.\n\nResults of the study will be implemented in (inter) national guidelines, to effect everyday practice.",[293,294,295,24,296],"Recurrent Miscarriage","Recurrent Pregnancy Loss","Habitual Abortion","Fertility Disorders",[298,299,300],"Recurrent pregnancy loss","Recurrent miscarriage","prednisolone","2024-05-23",{"date":303,"type":34},"2024-05-24",{"date":305,"type":34},"2024-01-29",{"date":307,"type":19},"2027-07-29",{"name":309,"class":41},"Leiden University Medical Center",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":110,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":55,"phases":320,"briefSummary":321,"conditions":322,"keywords":323,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":4},"100489461","interest-of-a-short-early-psychological-care-in-women-with-miscarriage-100489461","NCT05653414","Interest of a Short Early Psychological Care in Women With Miscarriage","Interest of a Short Early Psychological Care in Women With Miscarriage: a Controlled Randomized Study","MisTher","Inclusion Criteria:\n\n* women with an early miscarriage (defined by a spontaneous termination of pregnancy before the 14th week of amenorrhea)\n* women aged more than 18\n* women agreeing to participate in the study (signing the informed consent form).\n\nExclusion Criteria:\n\n* ectopic pregnancy\n* molar pregnancy\n* women with recurrent miscarriages\n* women less than 18",{"count":319,"type":19},932,[57],"Miscarriage is a very common complication of pregnancy, accounting for 15.3% (95% CI 12.5-18.7%) of diagnosed pregnancies. Miscarriage would affect one in ten women during her lifetime. Worldwide, 23 million miscarriages occur annually.\n\nBecause of its frequency, miscarriage isoften considered as trivial event by caregivers. Still, miscarriage can be a traumatic event. Literature is consistent on the psychological morbidity associated with miscarriage. Anxiety, depression, post-traumatic stress have been studied in women after miscarriage. Cohort studies and clinical trials suggest that psychological and supportive interventions performed in women after miscarriage may improve women's psychological well-being and reduce miscarriage complications in subsequent pregnancies. However, to date, the literature is considered insufficient on the psychological care of women after a miscarriage.",[24],[24,324,325,326,327],"Psychological care","Anxiety","Depression","Post traumatic stress disorder","2023-05-11",{"date":330,"type":34},"2023-05-15",{"date":332,"type":19},"2023-05-30",{"date":334,"type":19},"2026-12-01",{"name":336,"class":41},"Université de Reims Champagne-Ardenne"]